Regeneron Pharmaceuticals Inc (MEX:REGN)
MXN 16289.76 0 (0%) Market Cap: 1.82 Til Enterprise Value: 1.69 Til PE Ratio: 29.10 PB Ratio: 4.02 GF Score: 90/100

Regeneron Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript

May 20, 2019 / 02:00PM GMT
Release Date Price: MXN5878.59
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

Good morning. My name is Carter Gould, senior biotech analyst here at UBS. Next up is Regeneron Pharmaceuticals. Joining me onstage, Marion McCourt, SVP of Commercial; Jay Markowitz, Head of Portfolio Strategy. Both, thank you very much for joining us today. I'm going to keep going back and forth with the -- so like I said, thank you.

Questions & Answers

Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

I guess first question, we've got a lot to get through because you guys are one of the more diversified companies, lots of dynamic stuff to talk about.

I guess first thing, Jay, a question for you. You've been in the company around 3 years now, sort of you're -- over that 3 years, we've seen oncology really increase as a point of focus for the company. Can you maybe -- starting with Libtayo and then the bispecifics and the evolution of that and when I looked at sort of like your Phase I programs over the past year,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot